Skip to main content
Equibles
CTKB logo

CTKB · Cytek Biosciences, Inc. · Metrics

Track CTKB — free

Use CTKB with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CTKB.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$5.89 +0.30 (+5.37%) At close · Oct 26
Russell 2000 member Rebalance outlook locked
Market Cap
$765.60M
Shares
129.98M
Volume · Oct 26 1.24M Avg daily vol (3M) 1.13M

CTKB metrics

88 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$5.89
Market cap
$765.60M

Price action

20 metrics
Price change (1W)
+6.5%
Price change (30D)
-2.6%
Price change (3M)
+25.3%
Price change (6M)
+27.0%
Price change (YTD)
+10.7%
Price change (1Y)
+34.4%
Trailing year
Price change (5Y)
-76.7%
52-week high
$6.09
52-week low
$3.36
Change from 52-week high
-8.2%
Change from 52-week low
+66.6%
Annualized volatility
55.8%
Annualized volatility (3M)
50.3%
Beta
0.8
RSI (14D)
57.5
Price vs SMA 50
+8.8%
Price vs SMA 200
+20.5%
Avg volume (3M)
1.12M
Relative volume
0.6
Average dollar volume
$5.73M

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
129.98M

Valuation

12 metrics
P / E (TTM)
279.5
Trailing earnings · reciprocal yield 0.4%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
3.5×
reciprocal yield 28.4%
P / book
2.3
reciprocal yield 44.3%
FCF yield
-1.7%
TTM · current market cap
Buyback yield
0.6%
P / FCF
—
P / operating cash flow
—
Earnings yield
-11.1%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
0.6%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-11-04
Last earnings
2026-08-05

Profitability

9 metrics
Gross margin
53.2%
Operating margin
-21.6%
Trailing 12 months
Net margin
-39.0%
Gross profit (TTM)
$110.03M
Operating profit (TTM)
−$44.65M
Net income (TTM)
−$80.58M
Trailing 12 months
Diluted EPS (TTM)
$0.02
FCF margin
-5.8%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$1.61
Gross profit per diluted share (TTM)
$0.86
Operating profit per diluted share (TTM)
$-0.35
EBITDA per diluted share (TTM)
$-0.29
Net income per diluted share (TTM)
$-0.63
Operating cash flow per diluted share (TTM)
$-0.05
Free cash flow per diluted share (TTM)
$-0.09
Capital expenditures per diluted share (TTM)
$0.05
R&D per diluted share (TTM)
$0.29
Stock compensation per diluted share (TTM)
$0.17
Book value per share
$2.66

Growth

11 metrics
Revenue growth YoY
+5.6%
Year over year
Net income growth YoY
—
Revenue (TTM)
$206.71M
Trailing 12 months
EPS growth YoY
-550.0%
Shares change YoY
+2.0%
Year over year · more shares
Revenue CAGR (3Y)
+308.2%
Revenue CAGR (5Y)
+209.5%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-25.0%
Return on assets
-18.0%
Debt / equity
—
Current ratio
4.5
EBITDA (TTM)
−$36.96M
Free cash flow (TTM)
−$12.08M
Quick ratio
3.9
Interest coverage
-143.1
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$73.85M
Latest balance sheet
Cash & equivalents
$73.85M
Total assets
$446.93M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$6.04M
Capital expenditures (TTM)
$6.04M
R&D (TTM)
$37.26M
SG&A (TTM)
—
Stock compensation (TTM)
$21.36M
R&D / revenue
18.0%
Stock compensation / revenue
10.3%

Ownership (13F)

9 metrics
13F filers
154
13F filer change QoQ
-11
Institutional ownership
62.7%
Conviction holders (share of 13F filers)
1.3%
Crowding (high-turnover and private-fund holders)
31.0%
Private-fund adviser ownership
28.7%
Active holders' share change QoQ
+14.0%
Holder tenure
10.1
Price vs estimated holder cost
-46.5%

Ownership (registered funds)

1 metrics
Index-fund ownership
13.1%

Short interest

3 metrics
Short interest
3.4%
Latest settlement · 2.7 days to cover
Days to cover
2.7d
Short-squeeze score
54 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1831915 CUSIP 23285D109 13F (30d) 20 filings 20 filers Visit website Investor relations